Professional Marketing briefs

Share this article:
Novartis announced a reorganization of its US business into units focusing on primary care, MS, respiratory disease and neuroscience, along with a 20% reduction in its US headquarters staff. With Diovan going off-patent in 2012, it no longer makes sense for the company to focus its sales force on primary care physicians, CEO Joe Jimenez (left) said. He told The Wall Street Journal that the company would beef up its sales force in China using its own employees, bucking the trend towards outsourcing sales and research staff in China.  

Avanir Pharmaceuticals named Michael McFadden VP US sales and managed markets. McFadden, who joins from Amylin, will be responsible for staffing, training and managing the planned Zenvia specialty sales force. Avanir hopes to launch Zenvia for pseudobulbar affect, a neurological disease which causes uncontrollable laughing or crying, next year.

Specialty and hospital sales forces are no longer contracting, according to a Cutting Edge Information survey which found a leveling off of headcount and budget over the past two years. Daily calls by specialty and hospital reps was steady, said CEI, and per-rep visits for pharmas were up.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?